endpts.com·Jun 2, 2026
Legend Biotech has unveiled its first in vivo CAR-T data, marking a significant development in the field and contributing to a rise in biopharma sentiment, which is currently at its highest since the industry downturn. The results pertain to treatments for lymphoma, highlighting the company's ongoing advancements following its previous product, Carvykti.
The most valuable insight from this content is Legend Biotech's release of their first _in vivo_ CAR-T data, which indicates significant progress in the field of cellular therapies. For those tracking advancements in biotech and cell/gene therapy, this development presents an opportunity to assess potential shifts in treatment paradigms and investment prospects within the CAR-T landscape.